<DOC>
	<DOCNO>NCT01679080</DOCNO>
	<brief_summary>Osteogenesis imperfecta ( OI ) inherit disease connective tissue . Symptoms fracture , growth retardation , blue sclera , bad teeth , impair hearing a.o . The aim present study investigate effect treatment adult OI patient bisphosphonate ( zoledronic acid ) , parathyroid hormone ( PTH ) placebo bone mass , fracture risk quality life . The investigator therefore conduct double blind , placebo control trial , take genotype previous antiresorptive therapy account .</brief_summary>
	<brief_title>The Effect Treatment With Teriparatide Zoledronic Acid Patients With Osteogenesis Imperfecta</brief_title>
	<detailed_description />
	<mesh_term>Osteogenesis Imperfecta</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Teriparatide</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>clinical diagnosis osteogenesis imperfecta BMD &lt; 1.0 creatinine clearance &lt; 30mL/min treatment glucocorticoid &gt; 5mg daily last 3 month metabolic bone disease vitamin deficiency liver kidney disease contradiction zoledronic acid teriparatide increase baseline risk osteosarcoma</criteria>
	<gender>All</gender>
	<minimum_age>22 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Drug therapy</keyword>
	<keyword>Adult</keyword>
</DOC>